RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Studio dei meccanismi molecolari alla base dell’anomala proliferazione e funzione paratiroidea, e identificazione ed uso clinico di marcatori molecolari di carcinoma paratiroideo sporadico e familiare. Nuove acquisizione sulla prevalenza delle manifestazioni scheletriche, neuropsichiche e metaboliche dell’iperparatiroidismo primario, loro relazione con i polimorfismi del recettore del calcio ed effetti della paratiroidectomia.
• 2 - RUOLO DEGLI ORMONI IPOFISARI NELLE NEOPLASIE.
• 3 - Sviluppo e progressione del carcinoma epatocellulare: meccanismi molecolari ed implicazioni terapeutiche
• 4 - Cause, conseguenze, e aspetti terapeutici dell'iperomocisteinemia nell'uremia e nel diabete.
• 5 - Ruolo delle adipochine, citochine infiammatorie e linfociti T regolatori nel determinismo dell’aterosclerosi accelerata e della sindrome metabolica in corso di lupus eritematoso sistemico.
• 6 - Avanzamenti nella diagnosi molecolare e nel trattamento dei tumori neuroendocrini
• 7 - Effetti clinici e molecolari dell'eccesso di glucocorticoidi
• 8 - Implicazioni diagnostico-terapeutiche delle nuove conoscenze cliniche e molecolari del carcinoma midollare della tiroide.
• 9 - PROGRESSIONE DA MGUS A MIELOMA MULTIPLO: PATOGENESI MOLECOLARE, IDENTIFICAZIONE DI POTENZIALI MARCATORI PROGNOSTICI E SVILUPPO PRECLINICO DI RAZIONALI APPROCCI CHEMIOPREVENTIVI
• 10 - Ruolo dell'FGFR2 e di altri cofattori nell'etiopatogenesi di tumori epiteliali.

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze mediche
  • GENETICA MEDICA
  • ONCOLOGIA MEDICA
  • MEDICINA INTERNA
  • MALATTIE DELL'APPARATO CARDIOVASCOLARE
  • ENDOCRINOLOGIA

Classificazione brevettuale

• HUMAN NECESSITIES
  • MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES (bringing into special physical form A61J [N: mechanical aspects]; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; compounds per se C01, C07, C08, C12N; soap compositions C11D; micro-organisms per se C12N) [C0203]

Classificazione geografica

• Regione: Veneto

Bibliografia

1.Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000 Feb;85(2):637-44.
2. Jarolim L, Breza J, Wunderlich H. Adrenal tumours. Eur Urol. 2003 Jan;43(1):I-X.
Dackiw AP, Lee JE, Gagel RF, Evans DB. Adrenal cortical carcinoma. World J Surg. 2001 Jul;25(7):914-26.Review.
3.Sidhu S, Marsh DJ, Theodosopoulos G, Philips J, Bambach CP, Campbell P, Magarey CJ, Russell CF, Schulte KM, Roher HD, Delbridge L, Robinson BG. Comparative genomic hybridization analysis of adrenocortical tumors. J Clin Endocrinol Metab. 2002 Jul;87(7):3467-74.
4.Desvergne B, Wahli W. Peroxisome proliferator-actived receptors : nuclear control of metabolism. Endocrine Rev, 1999,20 :649-688.
5.Ferruzzi P, Ceni E, Tarocchi M, Grappone C, Milani S, Galli A, Fiorelli G, Serio M, Mannelli M. Thiazolidinediones Inhibit Growth and Invasiveness of the Human Adrenocortical Cancer LineH295R.JClinEndocrinolMetab.2005,90:1332-39.
6. Fang VS. Establishment and characterization of a strain of human adrenal tumor cells that secrete estrogen. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1067-71.
7. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Schmid KW, Mann K, Petersenn S.
Immunohistochemical determination of somatostatin receptor subtypes 1, 2A, 3, 4, and 5 in various adrenal tumors. Endocr Res. 2004 Nov;30(4):931-4.
8. Chan NN, Isaacs AJ. Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma. Postgrad Med J. 1999 Feb;75(880):96-7.
9. Kopf D, Goretzki PE, Lehnert H. Clinical management of malignant adrenal tumors. Cancer Res Clin Oncol. 2001;127(3):143-55.
10. Scarselli M, Novi F, Schallmach E, Lin R, Baragli A, Colzi A, Griffon N, Corsini GU, SokoloffP, Levenson R, Vogel Z, Maggio R. D2/D3 dopamine receptor heterodimers exhibit unique functional properties. J Biol Chem. 2001 Aug 10;276(32):30308-14.
11. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for doamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2000 Apr 7;288(5463):154-7.
12. Metab Res 2004,36:397–405 Fottner C, Hoeflich A, Wolf E, WeberMM Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Horm
13. Eur J Clin Invest. 2000 D41 J Psychosom Res. 2002 Oct;53(4):865-71.
Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress.
Tsigos C, Chrousos GP. 30 Suppl 3:69-75. Review.
14. Horm Metab Res. 2004 Jun;36(6):397-405. Review. Role of the insulin-like growth factor system in adrenocortical growth control and carcinogenesis. Fottner Ch, Hoeflich A, Wolf E, Weber MM.
15. Ann Epidemiol. 2005 Mar;15(3):202-206. Prevalence of the Metabolic Syndrome in Relation to Self-reported Cancer History. Ness KK, Oakes JM, Punyko JA, Baker KS, Gurney JG.
16. Endocr Res. 2000 Nov;26(4):905-10. Transforming growth factor beta1: implications in adrenocortical tumorigenesis. Arnaldi G, Freddi S, Mancini T, Kola B, Mantero F.
17. Oncogene. 2003 Sep 25;22(41):6408-23. Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of anti-apoptotic transcriptional programs and proto-oncogene stabilization. Iyengar P, Combs TP, Shah SJ, Gouon-Evans V, Pollard JW, Albanese C, Flanagan L, Tenniswood MP, Guha C, Lisanti MP, Pestell RG, Scherer PE.
18. Allolio, B, Hahner, S, Weismann, D & Fassnacht, M (2004). Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60: 273-87.
19. MacFarlane, DA (1958). Cancer of the adrenal cortex: the natural history, prognosis and treatment in the study of fifty cases. Ann R Coll Surg Engl 109: 613-618.
20. Allolio, B, Hahner, S, Weismann, D & Fassnacht, M (2004). Management of adrenocortical carcinoma. Clin Endocrinol (Oxf) 60: 273-87.
21. Vassilopoulou-Sellin, R, Guinee, VF, Klein, MJ, Taylor, SH, Hess, KR, Schultz, PN & Samaan, NA (1993). Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer. Cancer 71: 3119-23.
22. Wooten, MD & King, DK (1993). Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 72: 3145-55.
23. Venkatesh, S, Hickey, RC, Sellin, RV, Fernandez, JF & Samaan, NA (1989). Adrenal cortical carcinoma. Cancer 64: 765-9.
24. Luton, JP, Cerdas, S, Billaud, L, Thomas, G, Guilhaume, B, Bertagna, X, et al. (1990). Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med 322: 1195-201.
25. Schulick, RD & Brennan, MF (1999). Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol 6: 719-26.
26. Haak, HR, Hermans, J, van de Velde, CJ, Lentjes, EG, Goslings, BM, Fleuren, GJ & Krans, HM (1994). Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 69: 947-51.
27. Baudin, E, Pellegriti, G, Bonnay, M, Penfornis, A, Laplanche, A, Vassal, G & Schlumberger, M (2001). Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer 92: 1385-92.
28. Pommier, RF & Brennan, MF (1992). An eleven-year experience with adrenocortical carcinoma. Surgery 112: 963-70; discussion 970-1.
29. Bates, SE, Shieh, CY, Mickley, LA, Dichek, HL, Gazdar, A, Loriaux, DL & Fojo, AT (1991). Mitotane enhances cytotoxicity of chemotherapy in cell lines expressing a multidrug resistance gene (mdr-1/P-glycoprotein) which is also expressed by adrenocortical carcinomas. J Clin Endocrinol Metab 73: 18-29.
30. Terzolo M, Pia A, Ali A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, Borretta G, Angeli A. Adrenal incidentaloma: a new cause of the metabolic syndrome? J Clin Endocrinol Metab. 2002 Mar;87(3):998-1003.
31.Pittas AG,Nandini AJ,Greenberg AS. Adipocytokines and insulin resistance. J Clin Endocrinol Metab 2004,89:447
32.Fernàndez-Real JM,Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. End Rev 2003,24:278
33.Rifas L. Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. Calcified Tissue Int 1999,64:1
34.Kushlinskii NE,Britvin TA,Kazantseva IA et al. Serum interleukin-6 in patients with adrenal tumors. Bull Exp Bio Med 2004,137:273
35.Kershaw EE,Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004,89:2548
36.Conti B,Sugama S,Kim Y et al. Modulation of IL-18 in the adrenal cortex following acute ACTH or chronic corticosterone treatment. Neuroimmunomodulation 2000,8:1
37.Rifas L. Bone and cytokines: beyond IL-1, IL-6 and TNF-alpha. Calcified Tissue Int 1999,64:1
38.Krsek M,Silha JV,Jezkovà J et al. Adipokine levels in Cushing’s syndrome; elevated resistin levels in female patients with Cushing’s syndrome. Clin Endocrinol 2004,60:350
39.Malavazos AE, Cereda M,Morricone L et al. Monocyte chemoattractant protein 1 (MCP-1) and visceral fat. J Clin Endocrinol Metab 2005,90,in press
40.Zvonic S,Hogan JC,Arbur-Reily P et al. Effects of Cardiotrophin on Adipocytes. J Biol Chem 2004,279:47572
41.Chiodini I,Carnevale V,Torlontano M et al. Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrhoic patients with Cushing’s syndrome. J Clin Endocrinol Metab 1998,83:1863
42.Chiodini I,Guglielmi G,Battista C et al. Spinal volumetric bone mineral density and vertebral fractures in female patients with adrenal incidentalomas: the effect of subclinical hypercortisolism and gonadal status. J Clin Endocrinol Metab 2004,89:2237
43.Sartorio A,Conti A,Ferrero S et al. Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing’s syndrome and in patients with adrenal incidentaloma. Eur J Endocrinol 1998,138:146

Parole Chiave

CARCINOMA CORTICOSURRENALICO; MECCANISMI DI TUMORIGENESI; CHEMIOTERAPIA; MITOTANE; SINDROME CUSHING SUBCLINICO; INCIDENTALOMA SURRENALICO; RISCHIO CARDIOVASCOLARE; INSULINO-RESISTENZA; TURNOVER OSSEO